Argentina

/Tag:Argentina
­

Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay

Bionaturis has signed an exclusive development, manufacturing, registration, and commercialization license of its Leishmaniasis vaccine with the company Biotandil for Argentina and Paraguay
According to the terms of the license, Bionaturis will receive 50% of the profits resulting of the commercialization.
The immunization of these animals –the main reservoir of this neglected tropical disease- is crucial to avoid zoonosis episodes

 

Jerez de la Frontera, April 25, 2017.  Bionaturis has signed an exclusive development, manufacturing, registration, and commercialization license of its Leishmaniasis lead vaccine (BNT005) with the company Laboratorio Biologico de Tandil (Biotandil) for Argentina and Paraguay as the Territory. According to the terms of the license, Biotandil will be responsible for the manufacturing, development, registration, and commercialization of the vaccine in the territory. In exchange Bionaturis will receive 50% of the profits resulting of the commercialization.

Visceral Canine Leishmaniasis is a so called neglected tropical disease transmitted by the bite of the phlebotomine sandfly that acts as a vector. One of its main reservoir –spread through the Mediterranean countries and LATAM – are dogs, and therefore their immunization is crucial to minimize zoonosis episodes. According to WHO, in humans between 700.000 and 1.000.000 new cases, with 3% of deaths, are registered annually worldwide. In Argentina, there is in place a Leishmaniasis National Programme led to track its progress in the country and promoting control and eradication measures.

“This specific license of our Leishmaniasis vaccine candidate means a significant milestone because LATAM is one of the most affected regions by this disease, being recorded a steady growth in Argentine and Paraguay lately. Besides, getting the market authorization in Argentina could pave the way for its registration in other Latin American markets”, the chief of biological developments in Bionaturis, Juan Jose Infante, […]

April 25th, 2017|Blog english, Press Releases|Comments Off on Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR